Apple has faced challenges in incorporating advanced medical technology into its smartwatches, as highlighted by the recent sales halt on higher-end models of the Apple Watch. Analysts suggest that Apple may consider exploring licensing agreements or acquiring startups in the medical technology field to overcome these hurdles.
Previously, the International Trade Commission (ITC) ordered a sales halt on Apple Watch Series 9 and Ultra 2 due to a patent dispute with Masimo, a medical technology company. The dispute revolved around specific technologies related to a blood-oxygen measurement system. While Apple complied with the ITC ruling and temporarily discontinued online sales of the affected watches in the United States, a recent federal court action has lifted the sales halt on a temporary basis, allowing Apple to resume sales during the appeal process.
This is not the first time Apple has faced patent disputes in its efforts to transform its smartwatches into health-management devices. Last year, the ITC ruled that Apple had infringed on AliveCor’s wearable EKG technology. However, the Biden administration chose not to overturn the ruling, and another regulatory body declared AliveCor’s technology non-patentable, sparing Apple Watch sales from a direct impact. Nonetheless, legal battles continue.
Analysts, including Dan Ives from Wedbush Securities, suggest that Apple may pursue licensing partnerships or acquire startups specializing in medical technology to navigate the increasing number of patent hurdles. This strategy would enable Apple to incorporate advanced health features into its smartwatches while safeguarding its intellectual property rights.
FAQ
The source of the article is from the blog coletivometranca.com.br